Current status of iron overload and chelation with deferasirox

Choudhry, V. P.; Naithani, Rahul

doi:10.1007/s12098-007-0134-7

Cited by 22 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though some studies [26][27][28] have tried to correlate endocrine dysfunctions with iron chelation, this study has not specifically addressed this issue.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Growth, Puberty and Endocrine Dysfunctions in Relation to Iron Overload in Multi Transfused Indian Thalassemia Patients

2011

View full text Add to dashboard Cite

In this study analysis, short stature and hypogonadism were frequent findings. These results support the need for vigilant clinical evaluation of growth and puberty, as well as appropriate hormonal evaluation in poly transfused thalassemic children in order to detect and treat endocrine dysfunction early. The authors also recommend aggressive and adequate chelation from early life so that permanent damage to the endocrine glands can be prevented.

show abstract

“…Though some studies [26][27][28] have tried to correlate endocrine dysfunctions with iron chelation, this study has not specifically addressed this issue.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Growth, Puberty and Endocrine Dysfunctions in Relation to Iron Overload in Multi Transfused Indian Thalassemia Patients

2011

View full text Add to dashboard Cite

show abstract

“…It has satisfactory performance when applied to iron-overloaded patients undergoing long term blood transfusions (Choudhury and Naithani 2007;Yang et al 2007). However, despite its good cell permeability, it is practically insoluble in water, being classified as a Class II drug (poorly soluble, highly permeable) according to the Biopharmaceutics Classification System (BCS) (Food and Drug Administration 2015).…”

Section: Introductionmentioning

confidence: 99%

Deferasirox-TAT(47–57) peptide conjugate as a water soluble, bifunctional iron chelator with potential use in neuromedicine

et al. 2015

View full text Add to dashboard Cite

Deferasirox (DFX), an orally active and clinically approved iron chelator, is being used extensively for the treatment of iron overload. However, its water insolubility makes it cumbersome for practical use. In addition to this, the low efficacy of DFX to remove brain iron prompted us to synthesize and evaluate a DFX-TAT(47-57) peptide conjugate for its iron chelation properties and permeability across RBE4 cell line, an in vitro model of the blood-brain barrier. The water-soluble conjugate was able to remove labile iron from buffered solution as well as from iron overloaded sera, and the permeability of DFX-TAT(47-57) conjugate into RBE4 cells was not affected compared to parent deferasirox. The iron bound conjugate was also able to translocate through the cell membrane.

show abstract

“…7 It is marketed as Exjade and is mainly used is to reduce iron overload in patients who are receiving long-term blood transfusions as beta-thalassemia and other chronic anemias. 8 Silymarinis is an herbal remedy used for the treatment of liver and gall bladder disorders. Silymarin is a flavonoid complex extracted from milk thistle (Silybum marianum).It has a strong antioxidant,hepatoprotective, and iron chelating antivities.…”

mentioning

confidence: 99%

Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia

Hagag¹,

Elfarargy²,

El-Lateef³

2013

JAC

View full text Add to dashboard Cite

Abstract. Background: Beta thalassemia is an inherited hemoglobin disorder resulting in a severe, chronic anemia requiring life-long blood transfusion that induces iron overload. Silymarin is a flavonoid complex isolated from Silybin marianum with a strong antioxidant activity, inducing an hepatoprotective action, and probably, a protective effect on iron overload. The aim of this work was to determine the silymarin value in improving iron chelation in thalassemic patients with iron overload treated with Deferasirox. Patients and Methods: This study was conducted on 40 children with beta thalassemia major under follow-up at Hematology Unit, Pediatric Department, Tanta University Hospital with serum ferritin level more than 1000 ng/ml and was divided into two groups. Group IA: Received oral Deferasirox (Exjade) and silymarin for 6 months. Group IB: Received oral Deferasirox (Exjade) and placebo for 6 months and 20 healthy children serving as a control group in the period between April 2011 and August 2012 and was performed after approval from research ethical committee center in Tanta University Hospital and obtaining an informed written parental consent from all participants in this study. Results: Serum ferritin levels were markedly decreased in group IA cases compared with group IB (P= 0.001). Conclusion: From this study we concluded that, silymarin in combination with Exjade can be safely used in the treatment of iron-loaded thalassemic patients as it showed good iron chelation with no sign of toxicity. Recommendations: We recommend extensive multicenter studies in a large number of patients with longer duration of follow-up and more advanced techniques of assessment of iron status in order to clarify the exact role of silymarin in reducing iron overload in children with beta thalassemia.

show abstract

Current status of iron overload and chelation with deferasirox

Cited by 22 publications

References 23 publications

Evaluation of Growth, Puberty and Endocrine Dysfunctions in Relation to Iron Overload in Multi Transfused Indian Thalassemia Patients

Evaluation of Growth, Puberty and Endocrine Dysfunctions in Relation to Iron Overload in Multi Transfused Indian Thalassemia Patients

Deferasirox-TAT(47–57) peptide conjugate as a water soluble, bifunctional iron chelator with potential use in neuromedicine

Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia

Contact Info

Product

Resources

About